Technical Analysis for CTIC - Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 0.852 -2.06% -0.02
CTIC closed down 2.06 percent on Tuesday, September 17, 2019, on 45 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CTIC trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Calm After Storm Range Contraction -2.06%
Doji - Bearish? Reversal -2.06%
Upper Bollinger Band Walk Strength -2.06%
Wide Bands Range Expansion -2.06%
Above Upper BB Strength -2.06%
Overbought Stochastic Strength -2.06%

Older signals for CTIC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Cancer Chemical Compounds Organic Compounds Cancer Treatments Ovarian Cancer Acute Myeloid Leukemia Antibody Drug Conjugates Seattle Genetics Ethers Head And Neck Cancer Pyrrolidines Treatment Of Ovarian Cancer Treatment Of Acute Myeloid Leukemia Camidanlumab Tesirine Myelofibrosis Triple Negative Breast Cancer Pacritinib Pixantrone Treatment Of Head And Neck Cancer
Is CTIC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.3
52 Week Low 0.6
Average Volume 149,693
200-Day Moving Average 0.9501
50-Day Moving Average 0.7384
20-Day Moving Average 0.7495
10-Day Moving Average 0.7909
Average True Range 0.0417
ADX 21.63
+DI 26.2039
-DI 12.2708
Chandelier Exit (Long, 3 ATRs ) 0.7549
Chandelier Exit (Short, 3 ATRs ) 0.7651
Upper Bollinger Band 0.8711
Lower Bollinger Band 0.6279
Percent B (%b) 0.92
BandWidth 32.448299
MACD Line 0.0347
MACD Signal Line 0.0159
MACD Histogram 0.0188
Fundamentals Value
Market Cap 27.03 Million
Num Shares 31.7 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 2.78
Price-to-Book 2.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.90
Resistance 3 (R3) 0.90 0.89 0.89
Resistance 2 (R2) 0.89 0.88 0.89 0.89
Resistance 1 (R1) 0.87 0.87 0.87 0.87 0.88
Pivot Point 0.86 0.86 0.86 0.86 0.86
Support 1 (S1) 0.84 0.85 0.84 0.84 0.82
Support 2 (S2) 0.83 0.84 0.83 0.82
Support 3 (S3) 0.81 0.83 0.81
Support 4 (S4) 0.81